← back to search

Yago Nieto

The University of Texas MD Anderson Cancer Center · US
Area of research
Hematology · Pathology and Forensic Medicine
Research interest
Research interests include Multiple Myeloma Research and Treatments, Hematopoietic Stem Cell Transplantation, Lymphoma Diagnosis and Treatment, and Acute Myeloid Leukemia Research.
h-index
54
citations
14,389
works
711
NIH funding
primary concept
Medicine
email

Recent publications

Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network 2025cited by 7position: middledoi
Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis
Blood Advances 2023cited by 36position: middledoi
NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022
Journal of the National Comprehensive Cancer Network 2023cited by 18position: middledoi
Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant
JAMA Oncology 2021cited by 79position: middledoi
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma
Leukemia 2021cited by 78position: middledoi
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma
Blood Advances 2021cited by 47position: middledoi
Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network 2020cited by 110position: middledoi
Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era
Leukemia 2020cited by 37position: middledoi
Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial
The Lancet Haematology 2019cited by 102position: middledoi
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide–Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma
Biology of Blood and Marrow Transplantation 2019cited by 76position: middledoi
Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades
Biology of Blood and Marrow Transplantation 2019cited by 20position: middledoi
Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion
Blood 2018cited by 30position: middledoi
Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma
Biology of Blood and Marrow Transplantation 2018cited by 28position: middledoi
Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report
Cancer 2017cited by 86position: middledoi
Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis
Bone Marrow Transplantation 2017cited by 65position: middledoi
Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival
Biology of Blood and Marrow Transplantation 2017cited by 39position: middledoi
Prognostic Factors of Hepatosplenic T-cell Lymphoma
The American Journal of Surgical Pathology 2016cited by 82position: middledoi
Post-Transplant Outcomes in High-Risk Compared with Non–High-Risk Multiple Myeloma: A CIBMTR Analysis
Biology of Blood and Marrow Transplantation 2016cited by 41position: middledoi
Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma
Biology of Blood and Marrow Transplantation 2016cited by 22position: middledoi
Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma
Biology of Blood and Marrow Transplantation 2016cited by 19position: middledoi
Better allele-level matching improves transplant-related mortality after double cord blood transplantation
Haematologica 2015cited by 34position: middledoi
First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation 2012cited by 642position: middledoi
Cord-Blood Engraftment with Ex Vivo Mesenchymal-Cell Coculture
New England Journal of Medicine 2012cited by 474position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Parameswaran Hari · Medical College of Wisconsin2 papers (2017–2017)Anita D’Souza · Medical College of Wisconsin2 papers (2017–2017)Sairah Ahmed · The University of Texas MD Anderson Cancer Center2 papers (2015–2016)Tomer M. Mark · Genmab (United States)2 papers (2017–2017)Taiga Nishihori · Moffitt Cancer Center2 papers (2017–2017) · 2 papers (2012–2017)Saad Z. Usmani · Weill Cornell Medicine2 papers (2017–2017)Mingwei Fei · Medical College of Wisconsin2 papers (2017–2017)Corey Cutler · Harvard University1 papers (2012–2012)Marcos de Lima · The Ohio State University1 papers (2015–2015)David Marín · The University of Texas MD Anderson Cancer Center1 papers (2015–2015)Rohtesh S. Mehta · The University of Texas MD Anderson Cancer Center1 papers (2015–2015) · 1 papers (2016–2016)Benedetto Bruno · Department of Public Health1 papers (2017–2017)Brent A. Moore · University of Vermont1 papers (2015–2015) · 1 papers (2017–2017)Daniela Hoehn · AstraZeneca (United States)1 papers (2016–2016)Hillard Lazarus · Case Western Reserve University1 papers (2017–2017)Shahrukh K. Hashmi · Mayo Clinic1 papers (2017–2017) · 1 papers (2016–2016)